CAB LA — Competitive Intelligence Brief

CAB LA (CAB LA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Immunology / Infectious Disease.

phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase Immunology / Infectious Disease Small molecule

Target snapshot

CAB LA (CAB LA) — National Institute of Allergy and Infectious Diseases (NIAID). CAB LA is a long-acting injectable formulation of cabotegravir, an integrase strand transfer inhibitor (INSTI) that blocks HIV integration into host cell DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAB LA TARGET	CAB LA	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Tenofovir, Emtricitabine, Raltegravir	Tenofovir, Emtricitabine, Raltegravir	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI/NtRTI + INSTI)	HIV reverse transcriptase and HIV integrase
cabotegravir, CAB	cabotegravir, CAB	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

1. ViiV Healthcare · 12 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
3. Merck Sharp & Dohme LLC · 5 drugs in this class
4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
7. ANRS, Emerging Infectious Diseases · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. University of Colorado, Denver · 1 drug in this class
10. MU-JHU CARE · 1 drug in this class